Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Sunrise Air, an FDA-cleared rechargeable home sleep testing device, enables multi-night monitoring of sleep apnea using a minimalist chin sensor rather than traditional clinic-based polysomnography. This approach addresses both the practical barriers to diagnosis and the physiological reality that sleep patterns vary significantly night-to-night, making single-night clinical studies insufficient for accurate apnea detection.
Continuous hormonal monitoring via wearable technology addresses a fundamental gap in women's healthcare: annual or biannual blood tests cannot capture hormonal dynamics that fluctuate hourly and respond to immediate environmental and physiological pressures. This shift from static snapshots to real-time signal interpretation reframes how women's health is understood and managed.
Osteocalcin, a bone-derived hormone, activates protective mechanisms in the nervous system when estrogen declines following ovariectomy in mice. This finding identifies a compensatory endocrine pathway that may explain neurological resilience during menopause and suggests osteocalcin as a therapeutic target for estrogen-deficiency-related cognitive decline.
Oligomerix completed a Phase 1a trial of OLX-07010, an oral tau-targeting therapy showing favorable safety and appropriate drug exposure in healthy volunteers. The compound represents a shift toward preventive approaches in neurodegeneration by inhibiting tau protein misfolding rather than clearing existing damage.
Cognition Therapeutics has aligned with the FDA on a regulatory pathway for zervimesine (CT1812), an oral therapeutic showing efficacy in Phase 2 trials for dementia with Lewy bodies complicated by psychosis. This represents meaningful progress toward a registrational study for a condition with limited treatment options and significant cognitive and neuropsychiatric burden.
Beacon Biosignals demonstrates that at-home EEG monitoring paired with machine learning can detect sleep arousals with accuracy matching expert human raters, even in complex populations taking antidepressants. This advances sleep as a quantifiable biomarker for brain health and depression research without the confounding effects of laboratory environments.
Research over the past decade reveals ageism embedded in language patterns across healthcare, media, and social contexts—a finding that directly shapes how patients interpret health messaging and comply with medical guidance. The way aging is linguistically framed influences both psychological resilience and health behavior, making communication precision a measurable longevity factor.
Capsida Biotherapeutics terminated its Phase I/II trial of CAP-002, an AAV gene therapy for STXBP1 deficiency, following a patient death from cerebral edema during infusion. The company has not established a mechanistic explanation for the fatal adverse event, leaving critical safety questions unresolved for this therapeutic approach.
Oligomerix completed a Phase 1a safety study of OLX-07010, an oral tau self-association inhibitor, in 76 healthy volunteers across doses of 25–200 mg. The compound demonstrated a favorable safety profile and pharmacokinetic exposures consistent with efficacy thresholds observed in tau-mediated neurodegeneration models, supporting progression to Phase 1b patient studies.
Cala Health secured $50 million in growth capital to expand commercial access to the Cala kIQ System, an FDA-cleared wearable device that delivers personalized peripheral nerve stimulation to reduce hand tremors in essential tremor and Parkinson's disease. The device represents a shift toward precision, at-home neuromodulation therapy that addresses motor control dysfunction without systemic medication.
China has launched a standardized, competency-based education programme in longevity medicine for physicians, representing a systematic shift from reactive disease treatment to proactive healthspan management. This credential-granting initiative integrates geroscience, preventive care, digital technologies, and personalized interventions across multiple medical specialties to address age-related health challenges at scale.
Older adults frequently misjudge their own vision quality, reporting good sight despite objective testing that reveals significant impairment. This discordance between perceived and measured vision creates a critical gap in early detection, as self-assessment alone fails to identify declining visual function that accelerates age-related decline in other systems.